MedPath

Monalizumab

Generic Name
Monalizumab
Drug Type
Biotech
CAS Number
1228763-95-8
Unique Ingredient Identifier
3ZXZ2V0588

Overview

Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/03/25
Phase 2
Not yet recruiting
2024/07/16
Phase 2
Recruiting
2023/06/15
Phase 2
Recruiting
Hirva Mamdani
2022/02/03
Phase 3
Recruiting
2021/09/29
Phase 2
Recruiting
2020/10/19
Phase 3
Active, not recruiting
2020/04/03
Phase 2
Completed
2020/03/13
Phase 2
Completed
2019/02/07
Phase 2
Active, not recruiting
2019/01/14
Phase 1
Active, not recruiting

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

© Copyright 2025. All Rights Reserved by MedPath